BioCentury
ARTICLE | Company News

National Research Council Canada, Helix deal

March 3, 2017 7:49 PM UTC

NRC granted Helix worldwide rights to compound 2A3 for cancer indications. The license grants Helix the right to use the antibody in multiple systems, including CAR T cells, in combination with conjugates of the biotech's DOS47 technology and as a standalone therapeutic. ...